Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.69 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.59 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224617 | 0.89 | MTNR1A (0.76) | MTNR1AMTNR1BNQO2AKR1C3HDAC3 | |
| SCHEMBL24878466 | 0.85 | HTR6 (0.53) | MTNR1AMTNR1BNQO2AKR1C3HTR6 | |
| SCHEMBL1971963 | 0.85 | MTNR1A (0.72) | MTNR1AMTNR1BNQO2AKR1C3HTR6 | |
| SCHEMBL24878461 | 0.83 | AKR1C3 (0.53) | MTNR1AMTNR1BNQO2AKR1C3HTR6 | |
| SCHEMBL24877705 | 0.82 | MTNR1A (0.80) | MTNR1AHTR6 | |
| SCHEMBL30485879 | 0.82 | MTNR1A (0.80) | MTNR1AHTR6 | |
| SCHEMBL5616413 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2AKR1C3HTR6 | |
| SCHEMBL24878072 | 0.80 | HTR6 (0.57) | MTNR1AMTNR1BNQO2AKR1C3HTR6 | |
| SCHEMBL24878038 | 0.79 | HTR6 (0.49) | MTNR1AMTNR1BNQO2AKR1C3HTR6 | |
| SCHEMBL28920689 | 0.79 | AKR1C3 (0.55) | MTNR1AMTNR1BNQO2AKR1C3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | ALK, ACVR1, MUSK | MTNR1A 4177/4885MTNR1B 3437/4885NQO2 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.